![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, December 16, 2014 6:07:23 PM
Amgen purchased T-VEC from Biovex for $425M cash up front with milestone incentives totaling $1B in 2011:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=109088921
The efficacy and safety profile for T-VEC as a monotherapy was similar, but not quite as good as ONCS' ImmunoPulse.
The recent T-VEC/Yervoy combination results are very good and there is much excitement around the ImmunoPulse/Keytruda PD1 combination which may offer even better efficacy without side effects.
Why would you not be excited about such a combination? Clearly, leading experts in the field of oncology and immunology are. What technology interests you more and why?
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM